Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

Core Viewpoint - Novo Nordisk has appointed Maziar Mike Doustdar as the new president and CEO, effective August 7, 2025, succeeding Lars Fruergaard Jørgensen, who is stepping down on the same date [1][3]. Company Leadership Changes - Mike Doustdar, currently the executive vice president of International Operations, has a proven track record of driving growth, having more than doubled sales in International Operations to approximately DKK 112 billion in 2024 [2][10]. - Helge Lund, Chair of Novo Nordisk, expressed confidence in Doustdar's leadership abilities and vision for the company, emphasizing the need to address market challenges swiftly [3]. - Other executive changes include the merger of Research & Early Development and Development into a consolidated R&D unit, led by Martin Holst Lange, who will become the chief scientific officer [5][6]. Organizational Structure - Emil Kongshøj Larsen will succeed Mike Doustdar as executive vice president of International Operations, overseeing a region that accounts for about 20% of Novo Nordisk's global sales [8]. - The new executive management team will be effective from August 7, 2025, and will include various key members responsible for different operational areas [9]. Company Background - Novo Nordisk is a leading global healthcare company founded in 1923, focusing on chronic diseases, particularly diabetes, and employs approximately 77,400 people across 80 countries [13].